Interim measures awarded against European Medicines Agency


On April 25 2013 the president of the General Court of the European Court of Justice granted interim measures in favour of AbbVie and InterMune against the European Medicines Agency.

The interim measures prevented the agency from disclosing to third parties certain clinical data that these companies had filed relating to already authorised medicinal products (respectively Humira (INN adalimumab) and Esbriet (INN pirfenidone)) before the companies' respective challenges to the agency's proposed actions had been fully examined by the court.

Trevor Cook provides a report on this for ILO, read it in full here.